Viropro Key Fundamental Indicators

In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Viropro, as well as the relationship between them.

Viropro Total Revenue

689,601

Viropro's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Viropro's valuation are provided below:
Market Capitalization
18.3 K
Enterprise Value Revenue
11.7546
Quarterly Revenue Growth
1.19
We have found one hundred eleven available fundamental trend indicators for Viropro, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Viropro's current fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 3rd of March 2026, Market Cap is likely to drop to about 1.4 M. In addition to that, Enterprise Value is likely to drop to about 1.5 M This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
At this time, Viropro's Total Revenue is very stable compared to the past year. As of the 3rd of March 2026, Gross Profit is likely to grow to about 689.6 K, while Selling General Administrative is likely to drop about 1 M.
  
Build AI portfolio with Viropro Stock

Viropro Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.6 M2.4 MM
Slightly volatile
Other Current Liabilities17.5 K18.4 K23.7 K
Slightly volatile
Total Current Liabilities582.5 K591.4 K674.7 K
Slightly volatile
Accounts Payable365.2 K530.2 K456.2 K
Very volatile
Cash42.7 K67.8 K55.2 K
Slightly volatile
Long Term Debt388.5 K437.1 K477.1 K
Slightly volatile
Net Receivables125.5 K119.5 K100.1 K
Slightly volatile
Other Current Assets8.6 KK16.6 K
Slightly volatile
Total Liabilities712 K591.4 K710.9 K
Slightly volatile
Short and Long Term Debt258.1 K158 K209.8 K
Slightly volatile
Total Current Assets132.8 K198.8 K169.5 K
Pretty Stable
Short Term Debt258.1 K158 K209.8 K
Slightly volatile
Common Stock188.4 K360.5 K292.5 K
Pretty Stable
Property Plant Equipment69.6 K66.3 K55.6 K
Slightly volatile
Other Assets4.5 KK5.5 K
Slightly volatile
Good Will1.5 M1.7 M1.8 M
Slightly volatile

Viropro Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General AdministrativeM1.8 M1.5 M
Pretty Stable
Research Development123.1 K138.5 K151.1 K
Slightly volatile

Viropro Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock47.9 K50.4 K100.1 K
Slightly volatile
Change In Cash37.4 K35.6 K39.9 K
Slightly volatile
Other Cashflows From Financing Activities124.7 K195.5 K168.8 K
Pretty Stable
Depreciation23.5 K24.8 K65.3 K
Slightly volatile
Total Cash From Financing Activities441.8 K236.7 K303 K
Slightly volatile
Other Cashflows From Investing Activities45.3 K43.2 K44.9 K
Slightly volatile
Change To Netincome118.3 K110.7 K115.1 K
Slightly volatile
Change To Liabilities225 K214.3 K182.9 K
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.372.492.7296
Slightly volatile
Days Sales Outstanding38.3859.7762.2006
Very volatile
Average Payables356.2 K339.2 K351.8 K
Slightly volatile
Capex To Depreciation0.04820.05070.5925
Slightly volatile
EV To Sales2.592.733.0602
Slightly volatile
Sales General And Administrative To Revenue2.192.472.6961
Slightly volatile
Cash Per Share3.0E-43.0E-40.001
Slightly volatile
Income Quality0.520.770.6966
Slightly volatile
Intangibles To Total Assets0.60.80.8519
Pretty Stable
Current Ratio0.290.31.451
Slightly volatile
Receivables Turnover9.816.326.2016
Very volatile
Debt To Equity0.110.12050.176
Slightly volatile
Capex Per Share0.00.01.0E-4
Slightly volatile
Average Receivables1.3 K1.4 K1.6 K
Slightly volatile
Revenue Per Share0.00250.00270.0027
Slightly volatile
Interest Debt Per Share8.0E-49.0E-40.0021
Slightly volatile
Debt To Assets0.0710.07480.0976
Slightly volatile
Operating Cycle38.3859.7762.2006
Very volatile
Price Earnings To Growth Ratio0.02140.02250.2548
Slightly volatile
Company Equity Multiplier1.371.311.4146
Pretty Stable
Total Debt To Capitalization0.130.120.1339
Slightly volatile
Debt Equity Ratio0.110.12050.176
Slightly volatile
Quick Ratio0.290.31.451
Slightly volatile
Cash Ratio0.0980.10.9204
Slightly volatile
Cash Conversion Cycle38.3859.7762.2006
Very volatile
Days Of Sales Outstanding38.3859.7762.2006
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.820.90.9879
Slightly volatile
Fixed Asset Turnover16.3211.3910.9528
Very volatile
Debt Ratio0.0710.07480.0976
Slightly volatile
Price Sales Ratio2.372.492.7296
Slightly volatile
Asset Turnover0.20.240.2614
Pretty Stable

Viropro Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.4 M1.4 M1.3 M
Pretty Stable
Enterprise Value1.5 M1.6 M1.4 M
Very volatile

Viropro Operating Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Viropro is extremely important. It helps to project a fair market value of Viropro Stock properly, considering its historical fundamentals such as Operating Margin. Since Viropro's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Viropro's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Viropro's interrelated accounts and indicators.
Will Biotechnology sector continue expanding? Could Viropro diversify its offerings? Factors like these will boost the valuation of Viropro. If investors know Viropro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viropro data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Revenue Growth
1.19
Understanding Viropro requires distinguishing between market price and book value, where the latter reflects Viropro's accounting equity. The concept of intrinsic value - what Viropro's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viropro's price substantially above or below its fundamental value.
Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viropro's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

Viropro 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Viropro's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Viropro.
0.00
12/03/2025
No Change 0.00  0.0 
In 2 months and 31 days
03/03/2026
0.00
If you would invest  0.00  in Viropro on December 3, 2025 and sell it all today you would earn a total of 0.00 from holding Viropro or generate 0.0% return on investment in Viropro over 90 days. Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic... More

Viropro Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Viropro's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Viropro upside and downside potential and time the market with a certain degree of confidence.

Viropro Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Viropro's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Viropro's standard deviation. In reality, there are many statistical measures that can use Viropro historical prices to predict the future Viropro's volatility.
Hype
Prediction
LowEstimatedHigh
0.000.000.00
Details
Intrinsic
Valuation
LowRealHigh
0.000.000.00
Details

Viropro Backtested Returns

We have found zero technical indicators for Viropro, which you can use to evaluate the volatility of the company. The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Viropro are completely uncorrelated.

Auto-correlation

    
  0.00  

No correlation between past and present

Viropro has no correlation between past and present. Overlapping area represents the amount of predictability between Viropro time series from 3rd of December 2025 to 17th of January 2026 and 17th of January 2026 to 3rd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Viropro price movement. The serial correlation of 0.0 indicates that just 0.0% of current Viropro price fluctuation can be explain by its past prices.
Correlation Coefficient0.0
Spearman Rank Test1.0
Residual Average0.0
Price Variance0.0
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition

Based on the recorded statements, Viropro has an Operating Margin of -2.0906%. This is 94.04% lower than that of the Biotechnology sector and 98.13% lower than that of the Health Care industry. The operating margin for all United States stocks is 62.06% lower than that of the firm.

Viropro Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Viropro's current stock value. Our valuation model uses many indicators to compare Viropro value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Viropro competition to find correlations between indicators driving Viropro's intrinsic value. More Info.
Viropro is rated fifth in operating margin category among its peers. It is rated first in current valuation category among its peers . At this time, Viropro's Operating Profit Margin is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Viropro's earnings, one of the primary drivers of an investment's value.

Viropro Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viropro's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Viropro could also be used in its relative valuation, which is a method of valuing Viropro by comparing valuation metrics of similar companies.
Viropro is currently under evaluation in operating margin category among its peers.

Viropro Fundamentals

About Viropro Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Viropro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viropro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viropro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue656.8 K689.6 K
Sales General And Administrative To Revenue 2.47  2.19 
Ebit Per Revenue(1.57)(1.65)

Pair Trading with Viropro

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viropro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viropro will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Viropro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viropro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viropro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viropro to buy it.
The correlation of Viropro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viropro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viropro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viropro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Viropro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Viropro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Viropro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Viropro Stock:
Check out
To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Will Biotechnology sector continue expanding? Could Viropro diversify its offerings? Factors like these will boost the valuation of Viropro. If investors know Viropro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viropro data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Revenue Growth
1.19
Understanding Viropro requires distinguishing between market price and book value, where the latter reflects Viropro's accounting equity. The concept of intrinsic value - what Viropro's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viropro's price substantially above or below its fundamental value.
Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viropro's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.